#Dyslipidemia Therapeutics Market Size | Explore Tumblr posts and blogs

aditi-us · 6 years ago

Text

Global Dyslipidemia Therapeutics Market Size, Trends, Share, Key Player & Forecast until 2023

A Comprehensive research study conducted by KD Market Insights on " Dyslipidemia Therapeutics Market – By Product Type (Low-density Lipoproteins (LDL), Triglycerides), By Drug Class (Statins, Non-Statins, Combinations Drugs), By Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Stores, Mail Order Pharmacies) & Global Market Size, Trends, Share & Forecast 2018-2023" report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The Dyslipidemia Therapeutics Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments. Global Dyslipidemia Therapeutics market witnessed a market value of USD XX Million in 2017 and is estimated to reach USD XX million in 2023, registering a compound annual growth rate (CAGR) of XX% between 2017 and 2023. The market research report demonstrates market dynamics which includes growth drivers, restraining factors and opportunities and trends spearheading current nature and future status of this market. Our general approach is to target several individuals with specific questions that we believed would satisfy our research objective. Further, to speed up the data collection process, we employed an online survey, delivered via email. The research team analyzed the results to identify potential opportunities and risks for the market. Request for Sample @ https://www.kdmarketinsights.com/sample/3070 In addition, the report offers recent industry activities and value chain analysis for the Dyslipidemia Therapeutics Market. Moreover, Porter’s Five Forces analysis demonstrates the five forces which include buyers bargaining power, suppliers bargaining power, the threat of new entrants, the threat of substitutes, and degree of competition in Dyslipidemia Therapeutics Market. Along with figures and tables, a market attractiveness and BPS analysis has been provided for every segment in the report. The report analyses the market by geographies i.e. North America, Europe, Asia Pacific, Latin America & Middle East & Africa. Further, the geographies are fragmented into the country and regional groupings: - North America (U.S. & Canada) - Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe) - Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific) - Latin America (Brazil, Mexico, Argentina and Rest of Latin America) - Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa) Segmentation The research offers a comprehensive analysis of global Dyslipidemia Therapeutics market with respect to following sub-markets: Based on Product Type: - Low-density Lipoproteins (LDL) - Triglycerides Based on Drug Class: - Statins - Non-Statins - - - PCSK9 inhibitors - - - Cholesterol absorption inhibitors - - - Bile Acid resins - - - Fibrate - - - Others - Combinations Drugs Based on Distribution Channel: - Hospitals Pharmacies - Drug Stores - Retail Stores - Mail Order Pharmacies Competitive Landscape The report includes profiles of leading companies in the global Dyslipidemia Therapeutics market. Some of the key players profiled include: - AstraZeneca - Kowa Pharmaceuticals America, Inc - Merck & Co - Pfizer - Amgen - Sanofi - Novelion Therapeutics - Mylan - Abbott Laboratories - Novartis AG - Other Major & Niche Key Players Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/dyslipidemia-therapeutics-market Table of Contents: Research Methodology Market Definition and List of Abbreviations 1. Executive Summary 2. Growth Drivers & Issues in Global Dyslipidemia Therapeutics Market 3. Global Dyslipidemia Therapeutics Market Trends 4. Opportunities in Global Dyslipidemia Therapeutics Market 5. Recent Industry Activities, 2017 6. Porter's Five Forces Analysis 7. Market Value Chain and Supply Chain Analysis 8. Global Dyslipidemia Therapeutics Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 9. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Product Type 9.1. Introduction 9.2. Market Attractiveness, By Product Type 9.3. BPS Analysis, By Product Type 9.4. Low-density Lipoproteins (LDL) Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 9.5. Triglycerides Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Drug Class 10.1. Introduction 10.2. Market Attractiveness, By Drug Class 10.3. BPS Analysis, By Drug Class 10.4. Statins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5. Non-Statins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.1. PCSK9 inhibitors Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.2. Cholesterol absorption inhibitors Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.3. Bile Acid resins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.4. Fibrate Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.5. Others Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.6. Combinations Drugs Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Distribution Channel 11.1. Introduction 11.2. Market Attractiveness, By Distribution Channel 11.3. BPS Analysis, By Distribution Channel 11.4. Hospitals Pharmacies Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11.5. Drug Stores Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11.6. Retail Stores Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11.7. Mail Order Pharmacies Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 Continue… Check for Discount @ https://www.kdmarketinsights.com/discount/3070 About Us: KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market. Contact Us: KD Market Insights 150 State Street, Albany, New York, USA 12207 +1 (518) 300-1215 Email: [email protected] Website: www.kdmarketinsights.com

#Dyslipidemia Therapeutics Market #Dyslipidemia Therapeutics Market Size #Dyslipidemia Therapeutics Market Trends #Dyslipidemia Therapeutics Market Share #Dyslipidemia Therapeutics Market growth

0 notes

sophiajhon-blog · 6 years ago

Text

Global Dyslipidemia Therapeutics Market Size, Share, News, Trend, Demand, Opportunity by the end of 2023

A recent report by KD market insights titled as " Dyslipidemia Therapeutics Market – By Product Type (Low-density Lipoproteins (LDL), Triglycerides), By Drug Class (Statins, Non-Statins, Combinations Drugs), By Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Stores, Mail Order Pharmacies) & Global Market Size, Trends, Share & Forecast 2018-2023" provides the key trends, opportunities and challenges market will face in the forecasted period of 6 years i.e. 2019-2023. The study also provides the Dyslipidemia Therapeutics Market. competitors share and region wise analysis around the globe. Global Dyslipidemia Therapeutics market witnessed a market value of USD XX Million in 2017 and is estimated to reach USD XX million in 2023, registering a compound annual growth rate (CAGR) of XX% between 2017 and 2023. The market research report demonstrates market dynamics which includes growth drivers, restraining factors and opportunities and trends spearheading current nature and future status of this market. Our general approach is to target several individuals with specific questions that we believed would satisfy our research objective. Further, to speed up the data collection process, we employed an online survey, delivered via email. The research team analyzed the results to identify potential opportunities and risks for the market. Request for Sample @ https://www.kdmarketinsights.com/sample/3070 The report begins with an overview for Dyslipidemia Therapeutics Market. The research report broadly covers analysis of key market drivers, challenges, opportunities and trends. The study also provides separate analysis to understand market size, projections and macroeconomic indicators of global regions that affects the market share. The report also offers an extensive coverage of various industry players along with their recent product launches and market activities. The report also goes through porter’s five analyses for getting a better understanding about the forces that shape competition within the industry. There is a timeline considered for useful analysis i.e. 2017 is considered as base year, 2018 as estimated year and 2019-2023 as forecasted year. The market is divided into various segments and further sub-segments to drive the useful insights that can be utilized for company revenue growth and business. The Dyslipidemia Therapeutics Market is segmented on the basis of - Based on Product Type: - Low-density Lipoproteins (LDL) - Triglycerides Based on Drug Class: - Statins - Non-Statins - - - PCSK9 inhibitors - - - Cholesterol absorption inhibitors - - - Bile Acid resins - - - Fibrate - - - Others - Combinations Drugs Based on Distribution Channel: - Hospitals Pharmacies - Drug Stores - Retail Stores - Mail Order Pharmacies The research also does a separate geographical analysis that comprises both the region wise and country wise analysis. The geography covered in the report is North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe) , Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific) Latin America (Brazil, Mexico, Argentina and Rest of Latin America) and Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa). As per the report, Asia Pacific is likely to be the market giant in the upcoming years. Considering the competition, the major vendors providing Dyslipidemia Therapeutics Market across the globe are - - AstraZeneca - Kowa Pharmaceuticals America, Inc - Merck & Co - Pfizer - Amgen - Sanofi - Novelion Therapeutics - Mylan - Abbott Laboratories - Novartis AG - Other Major & Niche Key Players These vendors have adopted various types of organic and inorganic growth strategies, such as new product launches, business expansions, partnerships and collaborations, and mergers and acquisitions, to expand their offerings and further expand their presence in the Dyslipidemia Therapeutics Market. Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/dyslipidemia-therapeutics-market Table of Content Research Methodology Market Definition and List of Abbreviations 1. Executive Summary 2. Growth Drivers & Issues in Global Dyslipidemia Therapeutics Market 3. Global Dyslipidemia Therapeutics Market Trends 4. Opportunities in Global Dyslipidemia Therapeutics Market 5. Recent Industry Activities, 2017 6. Porter's Five Forces Analysis 7. Market Value Chain and Supply Chain Analysis 8. Global Dyslipidemia Therapeutics Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 9. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Product Type 9.1. Introduction 9.2. Market Attractiveness, By Product Type 9.3. BPS Analysis, By Product Type 9.4. Low-density Lipoproteins (LDL) Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 9.5. Triglycerides Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Drug Class 10.1. Introduction 10.2. Market Attractiveness, By Drug Class 10.3. BPS Analysis, By Drug Class 10.4. Statins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5. Non-Statins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.1. PCSK9 inhibitors Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.2. Cholesterol absorption inhibitors Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.3. Bile Acid resins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.4. Fibrate Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.5.5. Others Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 10.6. Combinations Drugs Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Distribution Channel 11.1. Introduction 11.2. Market Attractiveness, By Distribution Channel 11.3. BPS Analysis, By Distribution Channel 11.4. Hospitals Pharmacies Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11.5. Drug Stores Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11.6. Retail Stores Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 11.7. Mail Order Pharmacies Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12. Geographical Analysis 12.1. Introduction 12.2. North America Dyslipidemia Therapeutics Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12.2.1. By Product Type 12.2.2. By Drug Class 12.2.3. By Distribution Channel 12.2.4. By Country 12.2.4.1. Market Attractiveness, By End-user 12.2.4.2. BPS Analysis, By End-User 12.2.4.3. U.S. Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12.2.4.4. Canada Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12.3. Europe Dyslipidemia Therapeutics Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12.3.1. By Product Type 12.3.2. By Drug Class 12.3.3. By Distribution Channel 12.3.4. By Country 12.3.4.1. Market Attractiveness, By Country 12.3.4.2. BPS Analysis, By Country 12.3.4.3. Germany Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12.3.4.4. United Kingdom Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12.3.4.5. France Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 12.3.4.6. Italy Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023 Continue.... Check for Discount @ https://www.kdmarketinsights.com/discount/3070 About KD Market Insights KD Market Insights has come with the idea of helping business by intelligent decision making and thorough understanding of the industry. We offer a comprehensive database of syndicated research, customized reports as well as consulting services to help a business grow in their respective domain. At KD Market Insights, we offer our client a deep Market research reports accompanied by business consulting services that can help them to reach on top of the corporate world. Our customized reports are built by keeping all factors of the industry in mind. Contact Us 150 State Street, 3rd Floor, Albany, New York United States (12207) Telephone: +1-518-300-1215 Email: - [email protected] Website: - www.kdmarketinsights.com

#Dyslipidemia Therapeutics Market #Dyslipidemia Therapeutics Market size #Dyslipidemia Therapeutics Market share #Dyslipidemia Therapeutics Marketnews

0 notes

healthcaremrr · 2 years ago

Text

#Dyslipidemia Therapeutics Market

0 notes

globalaircraftgalley · 2 years ago

Text

Cardiometabolic Diseases Market Competitive Strategies, Advertising Trends, & Market Analysis by 2028

The Cardiometabolic Diseases Market is grow at a rate of 5.90% CAGR in the forecast period of 2021 to 2028. DBMR Research Report provide analysis & insight regarding various factor expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth.

Cardiometabolic illnesses are a group of metabolic conditions that raise the risk of individuals developing cardiovascular disease. Hypertension, central obesity, insulin resistance, dyslipidemia and glucose tolerance are some of these conditions. Patients are more likely to suffer from stroke, diabetes, or various types of heart disease as a result of these illnesses.

High consumption of fast food due to changing lifestyle which will result in higher rate of obesity and rising usage of biomarkers for diagnostic and risk assessment procedures are the driving factors which will influence the market growth rate. Furthermore, growing number of patients adopting pharmaceuticals and therapeutics owing to the proliferation of digital modes of drug delivery and innovations as well as advancements in technologies used for the drug delivery in healthcare industry are the factors that will expand the cardiometabolic diseases market. Also, increase in the proliferation of AI technology in the healthcare industry resulting in improved support services to the industry will act as a market driver and accelerate the growth rate.

Rise in the research and development activities and emerging markets will provide beneficial opportunities for the cardiometabolic diseases market in the forecast period of 2021-2028.

Cardiometabolic Diseases Market Insight

This Cardiometabolic Diseases market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info Cardiometabolic Diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Cardiometabolic Diseases Trends Segmentation

It is fragmented on the basis of -

Type

chronic/congestive heart failure, hypertension, type 2 diabetes, and obesity.

Treatment

ACE inhibitors, diuretics, glucophage, liposuction and others.

End user

clinic, hospital and others.

Request Access for Cardiometabolic Diseases Market Sample Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiometabolic-diseases-market

Cardiometabolic Diseases Industry Country Level Analysis

The countries covered in the global Cardiometabolic Diseases market report are the U.S., Canada and Mexico in North America, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Cardiometabolic Diseases Industry Share Analysis

· The major players covered in the Cardiometabolic Diseases market report are

· Alnylam Pharmaceuticals, Inc.;

· Arrowhead Pharmaceuticals, Inc.;

· Dicerna Pharmaceuticals, Inc.;

· Cardax, Inc.;

· Novartis AG;

· Novo Nordisk A/S;

· Boehringer Ingelheim International GmbH;

· Kowa Company, Ltd.

Access Full Report:- https://www.databridgemarketresearch.com/reports/global-cardiometabolic-diseases-market

Major TOC of the Cardiometabolic Diseases Report

Chapter One:

Chapter Two:

Get TOC of the Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiometabolic-diseases-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Cardiometabolic Diseases Market

0 notes

globalaircraft · 3 years ago

Text

Cardiometabolic Diseases Market Business Opportunities in 2022

The Alkylamines Market is grow at a rate of 5.90% CAGR in the forecast period of 2021 to 2028. DBMR Research Report provide analysis & insight regarding various factor expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth.

Rise in the research and development activities and emerging markets will provide beneficial opportunities for the cardiometabolic diseases market in the forecast period of 2021-2028.

📷

Cardiometabolic Diseases Market Insight

Cardiometabolic Diseases Trends Segmentation

It is fragmented on the basis of-

Type

chronic/congestive heart failure, hypertension, type 2 diabetes, and obesity.

Treatment

ACE inhibitors, diuretics, glucophage, liposuction and others.

End user

clinic, hospital and others.

Request Access for Cardiometabolic Diseases Market Sample Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiometabolic-diseases-market

Cardiometabolic Diseases Industry Country Level Analysis

Cardiometabolic Diseases Industry Share Analysis

The major players covered in the Cardiometabolic Diseases market report are

Alnylam Pharmaceuticals, Inc.;

Arrowhead Pharmaceuticals, Inc.;

Dicerna Pharmaceuticals, Inc.;

Cardax, Inc.;

Novartis AG;

Novo Nordisk A/S;

Boehringer Ingelheim International GmbH;

Kowa Company, Ltd.

Access Full Report:- https://www.databridgemarketresearch.com/reports/global-cardiometabolic-diseases-market

Major TOC of the Cardiometabolic Diseases Report

Chapter One:

Chapter Two:

Get TOC of the Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiometabolic-diseases-market

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Cardiometabolic Diseases Market

0 notes

pavanghage · 4 years ago

Text

Dyslipidemia Drugs Market 2021 Global Industry Analysis by Trends, Size, Share, Company Overview, Growth and Forecast by 2027

Dyslipidemia Drugs Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report:https://axelreports.com/request-sample/61500

A 360 degree outline of the competitive scenario of the Global Dyslipidemia Drugs Market is presented by Axel Reports Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the market’s future growth, wide-ranging analysis of these extensions on the market’s future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Reasons for buying this report:

It offers an analysis of changing competitive scenario.

For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.

It offers seven-year assessment of Global Dyslipidemia Drugs

It helps in understanding the major key product segments.

Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.

It offers regional analysis of Global Dyslipidemia Drugs Market along with business profiles of several stakeholders.

It offers massive data about trending factors that will influence the progress of the Global Dyslipidemia Drugs

Get ToC for the overview of the premium report @ https://axelreports.com/industry-analysis/2021-2027-global-and-regional-dyslipidem/61500

By Market Players: AstraZeneca Bristol-Myers Squibb Sanofi Merck Amgen Pfizer Cerenis Amarin Corporation Alnylam Pharmaceuticals Catabasis Pharmaceuticals Daiichi Sankyo GlaxoSmithKline Cipla Kadmon Pharmaceuticals Eli Lilly Daewoong Pharmaceutical CJ HealthCare JW Pharmaceuticals Esperion Therapeutics CKD Bio Lupin Pharmaceuticals By Type Statins Cholesterol absorption inhibitors Dyslipidemia injectable By Application Hospitals and Clinics Medical Laboratories Drug Stores Others

A detailed outline of the Global Dyslipidemia Drugs Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Dyslipidemia Drugs Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Dyslipidemia Drugs Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Dyslipidemia Drugs Market. The feasibility of the new report is also measured in this research report.

Make an Enquiry for purchasing this Report :https://axelreports.com/enquiry-before-buying/61500

Table of Contents:

Global Dyslipidemia Drugs Market Overview

Economic Impact on Industry

Market Competition by Manufacturers

Production, Revenue (Value) by Region

Production, Revenue (Value), Price Trend by Type

Market Analysis by Application

Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Global Dyslipidemia Drugs Market Forecast

ABOUT US:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact: Axel Reports Akansha G (Knowledge Partner) Office No- B 201 Pune, Maharashtra 411060 Phone: US +18488639402 Email: [email protected]/ Web: https://axelreports.com/

#Dyslipidemia Drugs Dyslipidemia Drugs Market Application Dyslipidemia Drugs Market Drivers Dyslipidemia Drugs Market Dynamics Dyslipidemia

0 notes

pratikwadekar2 · 5 years ago

Text

Dyslipidemia Market Strategic Insights and key Business Influencing Factors | Major Players – Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals.

Dyslipidemia Market is a condition in which the levels of lipids (cholesterol, triglycerides, or both) or low high-density lipoprotein (HDL) cholesterol level elevated due to multiple reasons including lifestyle, genetics-disorders, drugs etc. According to World Health Organization, there were approximately 17.9 million people in 2016, who died from cardiovascular diseases, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.

Global Dyslipidemia is expected to rise gradually to an estimated value of USD 27.52 billion by 2026, registering a CAGR of 10.50% in the forecast period of 2019-2026 with the annual sales of USD 12.38 billion in the year of 2018. This rise in market value can be attributed to the increase in prevalence and awareness along with concerns regarding the health of patients.

Get Sample Report at :

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dyslipidemia-market

Competitive Analysis: Global Dyslipidemia Market

Few of the major competitors currently working in Global Dyslipidemia Market are AstraZeneca (UK), Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla Inc., CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, Lupin Pharmaceuticals and few among others.

Key Pointers Covered in the Global Dyslipidemia Market Trends and Forecast to 2026

Global Dyslipidemia Market New Sales Volumes

Global Dyslipidemia Market Replacement Sales Volumes

Global Dyslipidemia Market Installed Base

Global Dyslipidemia Market By Brands

Global Dyslipidemia Market Size

Global Dyslipidemia Market Procedure Volumes

Global Dyslipidemia Market Product Price Analysis

Global Dyslipidemia Market Healthcare Outcomes

Global Dyslipidemia Market Cost of Care Analysis

Global Dyslipidemia Market Regulatory Framework and Changes

Global Dyslipidemia Market Prices and Reimbursement Analysis

Global Dyslipidemia Market Shares in Different Regions

Recent Developments for Global Dyslipidemia Market Competitors

Global Dyslipidemia Market Upcoming Applications

Global Dyslipidemia Market Innovators Study

Get Detailed TOC:

https://www.databridgemarketresearch.com/toc/?dbmr=global-dyslipidemia-market

Key Developments in the Market:

In the year 2018, Sanofi and Regeneron Pharmaceuticals, Inc. announced that Praluent (alirocumab) in phase 3 clinical trialdemonstrated the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event such as a heart attack.

In the year 2018, Amgen Inc. announced the launch of Repatha (Evolocumab) in the US for the indication of heart attacks and stroke due to high cholesterol at a reduced price to gain more customers.

In the year 2015, WuXi PharmaTech announced its partnership with Eli Lilly to develop, manufacture, and commercializes in China a Lilly-discovered oral experimental drug for cardiovascular risk in patients with dyslipidemia.

Market Drivers

Increase in global geriatric population

Increase in prevalence of lifestyle diseases

Rise in acceptance of telemental health

Increase in availability of generic drugs

Market Restraints

Lack of R&D initiatives in this area.

patent expiry for some blockbuster drugs

Fewer Government initiatives taken in this direction.

Inquire Before Buying:

https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-dyslipidemia-market

Key insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Browse Related Report Here:

Glomerular Disease Therapeutics Market

Asia Pacific Drug Delivery Devices Market

#Dyslipidemia Market #Dyslipidemia Market share #Dyslipidemia Market size #Dyslipidemia Market trends #Dyslipidemia Market news #Dyslipidemia Market report #Dyslipidemia Market growth #Dyslipidemia Market forecast

0 notes

thesittingduck · 4 years ago

Text

caduet tablets Uses, Dosage, Side Effects, Precautions & Warnings

Drug Online

caduet Generic drug of the Therapeutic class: Cardiology and angiology Active ingredients: Amlodipine , Atorvastatin

what is caduet medication?

This medication is supplied as blue, oval-shaped, film-coated tablets debossed with “Pfizer” on one side and “CDT 101” on the other side.

Boxes of 7, 10, 14, 20, 28, 30, 50, 56, 60, 90, 100 or 200 tablets.

Not all presentations may be marketed.

what is caduet medication used for and indication?

CADUET is indicated for the prevention of cardiovascular events in hypertensive patients with 3 associated cardiovascular risk factors, with normal to moderately elevated cholesterol without established coronary artery disease, and in whom, according to current recommendations, the concomitant use of amlodipine and a low dose of atorvastatin is suitable .

CADUET should be used when the response to regimen and other non-pharmacological measures is inadequate.

caduet dosage

Oral route

The usual starting dose is 5 mg / 10 mg once daily.

If tighter blood pressure control is required, a dosage of 10 mg / 10 mg once daily may be administered.

The tablets can be taken at any time of the day, with or without food.

CADUET can be used alone or in combination with other antihypertensive drugs, but it must not be used in combination with other calcium channel blockers or another statin.

The combination of CADUET and fibrates should generally be avoided (see sections 4.4 and Interactions with other medicinal products and other forms of interaction ).

Patients with renal impairment : No dosage adjustment is necessary in patients with impaired renal function (see sections 4.4 and Pharmacokinetic properties ).

Patients with hepatic impairment : CADUET is contraindicated in patients with active hepatic disease.

Children / Adolescents : The safety and efficacy of CADUET have not been established in children / adolescents. Therefore, the use of CADUET is not recommended in this population.

Elderly : It does not appear necessary to adjust the dose in the elderly (see section Pharmacokinetic properties ).

Combination with other medicinal products : In combination with ciclosporin, the dose of atorvastatin should not exceed 10 mg (see section Interactions with other medicinal products and other forms of interaction ).

Contraindications

CADUET is contraindicated in patients:

Being hypersensitive to dihydropyridines *, to amlodipine, to atorvastatin or to any of the excipients of this medicine,

have active liver disease or a persistent and unexplained increase in serum transaminases exceeding 3 times the upper limit of normal,

In women who are pregnant, breastfeeding or of childbearing potential and not using reliable contraceptive methods (see section Pregnancy and breast-feeding ),

In combination with itraconazole, ketoconazole, telithromycin (see section Interactions with other medicinal products and other forms of interactions ),

having severe hypotension,

Having shock (including cardiogenic shock),

Having an obstruction of the efferent pathway to the left ventricle (for example severe aortic stenosis),

With haemodynamically unstable heart failure after acute myocardial infarction.

* amlodipine is a calcium channel blocker derived from dihydropyridine.

HOW TO TAKE CADUET?

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if in doubt.

Adults

The recommended starting dose of CADUET is one 5 mg / 10 mg tablet per day. Your doctor may increase the dose if necessary to 1 tablet of CADUET 10 mg / 10 mg per day.

The tablets should be swallowed whole with a glass of water. They can be taken at any time of the day, with or without food. However, it is best to take them at the same time each day.

Continue to follow your doctor’s dietary advice, especially to eat a low fat diet, avoid tobacco, and exercise regularly.

If you have the impression that the effect of CADUET tablets is too strong or too weak, talk to your doctor or pharmacist.

Use in children and adolescents

This medication is not recommended for children and adolescents.

If you take more CADUET 10 mg / 10 mg film-coated tablets than you should

If you accidentally take too many CADUET tablets (more than your usual dose), ask your doctor or the nearest hospital for advice. Take any remaining tablets, the carton or the whole carton with you so that hospital staff can quickly identify which medicine you have taken.

If you forget to take CADUET 10 mg / 10 mg film-coated tablets

If you forget to take your dose of CADUET, take your next dose at the normal time.

Do not take a double dose to make up for the dose you forgot to take.

If you stop taking CADUET 10 mg / 10 mg film-coated tablets

Do not stop taking CADUET unless your doctor tells you to.

If you have any further questions on the use of this medicine or want to stop taking your treatment, ask your doctor or pharmacist for more information.

How To Store Caduet?

Keep this medication out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister, the carton and the vial after “EXP”. The expiration date refers to the last day of that month.

Store at a temperature not exceeding 30 ° C.

Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

caduet side effects

The safety of CADUET has been evaluated in double-blind, placebo-controlled studies in 1092 patients treated for concomitant hypertension and dyslipidemia. During clinical trials with CADUET, no specific adverse events specific to this combination were observed.

Adverse events were limited to those previously reported for amlodipine and / or atorvastatin (see table of adverse events below).

In controlled clinical trials, discontinuation of treatment due to clinical adverse events or laboratory abnormalities was observed in 5.1% of patients treated with amlodipine and atorvastatin versus 4.0% of patients treated with amlodipine and atorvastatin. patients taking a placebo.

The adverse events below, listed according to MedDRA system organ classification and frequency order, relate to amlodipine and atorvastatin individually.

Very common: ³ 1/10, common: ³ 1/100 and <1/10, infrequent: ³ 1/1000 and <1/100, rare: ³ 1/10000 and <1/1000, very rare: < 1 / 10,000, frequency not known (cannot be estimated from the available data).

MedDRA

System organ classes

Side effects

Frequency

Amlodipine

Atorvastatin

Infections and infestations

Nasopharyngitis

–

Frequent

Blood and lymphatic system disorders

Leukopenia

Very rare

–

Thrombocytopenia

Very rare

Rare

Immune system disorders

hypersensitivity

Very rare

Frequent

Anaphylaxis

–

Very rare

Metabolism and nutrition disorders

Hyperglycemia *

Very rare

Frequent

Weight gain

Infrequent

Weightloss

Infrequent

–

Hypoglycemia

–

Infrequent

Anorexia

–

Infrequent

Psychiatric disorders

Insomnia

Infrequent

Mood disorders (including anxiety)

Infrequent

–

Nightmares

–

Infrequent

Depression

Infrequent

Frequency not known

Confusion

Rare

–

Disorders of the system nervous

Drowsiness

Frequent

–

Dizziness

Frequent

Infrequent

Headache (especially at the start of treatment)

Frequent

Tremors

Infrequent

–

Hypoesthesias, paresthesias

Infrequent

Syncope

Infrequent

Hypertonia

Very rare

–

Peripheral neuropathy

Very rare

Rare

Amnesia

–

Infrequent

Dysgeusia

Infrequent

Extrapyramidal syndrome

Frequency not known

–

Eye disorders

Blurred vision

–

Infrequent

Visual disturbances (including diplopia)

Infrequent

Rare

Ear and labyrinth disease

Tinnitus

Infrequent

Hearing loss

–

Very rare

Cardiac disorders

Palpitations

Frequent

–

Angina pectoris

Rare

–

Myocardial infarction

Very rare

–

Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)

Very rare

–

Vascular disorders

Flushing

Frequent

–

Hypotension

Infrequent

–

Vasculitis

Very rare

–

Respiratory, thoracic and mediastinal disorders

Pharyngolaryngeal pain

–

Frequent

Epistaxis

–

Frequent

Dyspnea

Infrequent

–

Rhinitis

Infrequent

–

Cough

Very rare

–

Interstitial lung disease, especially during long-term treatment

Frequency not known

Gastrointestinal disorders

Gingival hyperplasia

Very rare

–

Nausea

Frequent

Upper and lower abdominal pain

Frequent

Infrequent

Vomiting

Infrequent

Dyspepsia

Infrequent

Frequent

Changes in intestinal transit (including diarrhea and constipation)

Infrequent

–

Dry mouth

Infrequent

–

Dysgeusia

Infrequent

–

Diarrhea, constipation, gas

–

Frequent

Gastritis

Very rare

–

Pancreatitis

Very rare

Infrequent

Eructation

–

Infrequent

Hepatobiliary disorders

Hepatitis

Very rare

Infrequent

Cholestasis

–

Rare

Jaundice

Very rare

–

Hepatic insufficiency

–

Very rare

Skin and subcutaneous tissue disorders

Bullous dermatosis including erythema multiforme

Very rare

Rare

Angioedema

Very rare

–

Erythema multiforme

Very rare

–

Alopecia

Infrequent

Purpura

Infrequent

–

Skin discoloration

Infrequent

–

Pruritus

Infrequent

Eruption

Infrequent

Hyperhidrosis

Infrequent

–

Exanthema

Infrequent

–

Urticaria

Very rare

Infrequent

Angioneurotic edema

Very rare

Rare

Exfoliative dermatitis

Very rare

–

Photosensitivity

Very rare

–

Stevens-Johnson syndrome

Very rare

Rare

Bullous erythroderma with epidermolysis

–

Rare

Musculoskeletal and connective tissue disorders

Swelling of the joints (including swelling of the ankles)

Frequent

Arthralgia, myalgia

(see section Warnings and precautions for use )

Infrequent

Frequent

Muscle cramps, muscle spasms

Infrequent

Frequent

Back pain

Infrequent

Frequent

Neck pain

–

Infrequent

Pain in extremity

–

Frequent

Muscle fatigue

–

Infrequent

Myositis (see section Warnings and precautions for use )

–

Rare

Rhabdomyolysis, myopathy

(see section Warnings and precautions for use )

–

Rare

Tendinopathies, in rare cases tendon rupture

–

Rare

Immune-mediated necrotizing myopathy

–

Frequency not known

Kidney and urinary tract disorders

Urination disorder, nocturia, pollakiuria

Infrequent

–

Reproductive system and breast disorders

Incapacity

Infrequent

Gynecomastia

Infrequent

Very rare

General disorders and administration site conditions

Edema

Frequent

Infrequent

Peripheral edema

–

Infrequent

Tired

Frequent

Infrequent

Chest pain

Infrequent

Asthenia

Infrequent

Pain

Infrequent

–

Discomfort

Infrequent

Fever

–

Infrequent

Investigations

Increased liver enzymes: alanine aminotransferase, aspartate aminotransferase (mainly related to cholestasis)

Very rare

Frequent

Blood CK increased (see section 4.4 )

–

Frequent

Leukocyturia

–

Infrequent

* Diabetes: The frequency depends on the presence or absence of risk factors (fasting blood sugar ³ 5.6 mmol / l, BMI> 30 kg / m², increased triglyceride levels, history of high blood pressure).

caduet Interactions

Taking other medications

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Some medicines may interact with CADUET 10 mg / 10 mg film-coated tablets. This interaction may cause one or both of the medicines to be less effective, or on the contrary, this interaction may increase the risk or severity of side effects, including major muscle disorders known as rhabdomyolysis and myopathy (see section 4). .

Some medicines may interact with CADUET 10 mg / 10 mg film-coated tablets:

certain antibiotics such as rifampicin or certain “macrolide” antibiotics such as erythromycin, clarithromycin, telithromycin, fusidic acid or certain drugs used to treat infections caused by fungi such as ketoconazole, itraconazole,

medicines used to regulate lipid levels: fibrates, such as gemfibrozil or colestipol,

medicines used to regulate your heart rhythm, such as amiodarone, diltiazem and verapamil,

medicines used to treat or prevent seizures such as carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone,

medicines used to change how your immune system works, such as cyclosporin

protease inhibitors such as ritonavir, indinavir, nelfinavir used in the treatment of HIV,

medicines used to treat depression, such as nefazodone and imipramine,

medicines used to treat mental disorders, such as neuroleptics,

medicines used to treat heart failure, such as beta blockers

medicines used to treat high blood pressure, such as angiotensin II inhibitors, converting enzyme inhibitors, verapamil and diuretics,

alpha blockers used to treat high blood pressure or prostate problems

other medicines known to interact with CADUET 10 mg / 10 mg film-coated tablets such as ezetimibe (which lowers cholesterol), warfarin (which decreases blood clotting), oral contraceptives, stiripentol (an anticonvulsant used for treatment of epilepsy), cimetidine (used for heartburn and stomach ulcers), phenazone (a pain reliever), antacids (containing aluminum or magnesium, used to relieve problems stomach), and amifostine (used to treat cancer),

sildenafil (used in the treatment of erectile dysfunction, impotence),

dantrolene and baclofen (muscle relaxants),

steroids,

over-the-counter St. John’s Wort products.

CADUET may lower your blood pressure further if you are already taking other medicines to treat your high blood pressure.

If you are taking or have recently taken any other medicines, including medicines obtained without a prescription, talk to your doctor or pharmacist.

INTERACTIONS OF CADUET 10 MG / 10 MG WITH FOOD AND DRINK

Food and drinks

CADUET 10 mg / 10 mg film-coated tablets can be taken at any time of the day, with or without food.

Grapefruit juice

Do not take more than one or two glasses of grapefruit juice per day as large amounts of grapefruit juice may affect the effects of CADUET 10 mg / 10 mg film-coated tablets.

Alcohol

Avoid drinking too much alcohol while taking CADUET 10 mg / 10 mg film-coated tablets. See also section 2 “Take special care with CADUET 10 mg / 10 mg film-coated tablets” for more details.

Drive and use machines

Do not drive or use machines if you feel dizzy after taking this medicine.

Warnings and Precautions

Heart failure

Liver function monitoring

Clinical signs of hepatic dysfunction

Increased transaminases

Heavy alcohol consumption

Hepatic insufficiency

History of liver disease

Predisposing factor to the occurrence of rhabdomyolysis

Subject over 70 years of age

Unexplained muscle pain

Muscle cramp

Muscular weakness

Increase in CPK

Rhabdomyolysis

History of hemorrhagic stroke

History of lacunar infarction

Interstitial lung disease

Risk of diabetes

Woman of childbearing age

Heart failure

Patients with heart failure should be treated with caution. In a long-term placebo-controlled study in patients with severe heart failure (NYHA class III and IV), the reported incidence of pulmonary edema was higher in the amlodipine group compared to the placebo group. (see section Pharmacodynamic properties). Calcium channel blockers including amlodipine should be used with caution in patients with congestive heart failure because they may increase the risk of cardiovascular events and mortality.

Liver effects

Liver function tests should be performed before the start of treatment and then regularly after initiation of treatment, as well as in the event of signs or symptoms suggestive of liver damage. In the event of elevation of the serum transaminase level, monitoring is necessary until normalization.

A persistent increase in ALT or AST exceeding 3 times the upper limit of normal (ULN), should lead to discontinuation of treatment.

The half-life of amlodipine is increased and its AUC (Area Under the Curve) is greater in patients with hepatic impairment; dosage recommendations have not been established.

Due to the presence of atorvastatin, CADUET should be used with caution in patients who consume large amounts of alcohol, in patients with hepatic impairment and / or a history of liver disease.

Muscle effects

Like other HMG-CoA reductase inhibitors, atorvastatin can affect skeletal muscles and lead to myalgia, myositis and myopathies. These muscle damage may rarely progress to rhabdomyolysis, characterized by high levels of creatine kinase (CK) (more than 10 times the ULN), myoglobinemia and myoglobinuria which can lead to kidney failure, and in some cases be fatal.

Regular testing of CK or other muscle enzymes is not recommended in asymptomatic patients treated with statins. However, dosing of CKs is recommended before initiating statin therapy in patients with predisposing factors to rhabdomyolysis as well as in those with muscle symptoms during statin therapy (see below).

Very rare cases of autoimmune-mediated necrotizing myopathies (IMNM) have been reported during or after treatment with certain statins. IMNM is clinically characterized by proximal muscle weakness and increased serum creatine kinase, which persist despite discontinuation of statin therapy.

Before initiation of treatment

CADUET should be prescribed with caution in patients with predisposing factors to rhabdomyolysis. Before starting treatment with a statin, creatine kinase (CK) levels should be checked in the following situations:

Renal failure.

Hypothyroidism.

Personal or family history of genetic muscle diseases.

Personal history of muscle toxicity during treatment with a statin or a fibrate.

History of liver disease and / or excessive alcohol consumption.

In elderly patients (> 70 years), the need for these measures should be assessed, depending on the presence of other factors predisposing to rhabdomyolysis.

Situations in which increased plasma concentrations may occur, due to interactions (see section 4.5) and use in special populations including genetic polymorphisms (see section 5.2). ).

In these situations, a regular reassessment of the benefit / risk of the treatment, as well as regular clinical monitoring is recommended.

If the initial CK level is significantly elevated (more than 5 times the ULN) treatment should not be started.

Creatine kinase measurement

Creatine kinase (CK) should not be measured after heavy exercise or in the presence of another possible cause of increased CK, as this will make interpretation of the results difficult. In the event of a significant elevation of CK (more than 5 times the ULN) before treatment, this should be systematically checked again within 5 to 7 days to confirm the results.

During treatment

It is recommended that patients be asked to promptly report any unexplained muscle pain, muscle cramps or weakness, particularly if accompanied by malaise or fever.

· If symptoms appear when a patient is under treatment with CADUET, a CK levels should be measured; if the CK level is significantly elevated (more than 5 times the ULN), treatment should be discontinued.

· If muscular symptoms are severe and cause daily discomfort, discontinuation of treatment should be considered, even if CK levels did not exceed 5 times the ULN.

· If symptoms resolve and CK levels return to normal, the reintroduction of CADUET may be considered at the lowest dose and under close supervision.

Treatment with CADUET should be discontinued in the event of a clinically significant increase in CK level (> 10 times the ULN) or if rhabdomyolysis is diagnosed or suspected.

Amlodipine has no effect on laboratory parameters.

Combinations with other drugs

As with other statins, the risk of rhabdomyolysis is increased when CADUET is administered in combination with certain drugs which may increase the plasma concentration of atorvastatin, such as strong inhibitors of CYP3A4 or protein transporters (eg, cyclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, determovir and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir, etc / ritonavir). The risk of myopathy may also be increased in combination with gemfibrozil and other fibrates, antivirals used in the treatment of hepatitis C (HCV) (boceprevir, telaprevir, elbasvir / grazoprevir), erythromycin, niacin, l ‘ ezetimibe or colchicine. Therapeutic alternatives (not exhibiting these interactions) should be considered as far as possible.

In the event that the combination of these medicinal products with CADUET is necessary, the benefit / risk of concomitant treatments should be carefully assessed and appropriate clinical monitoring is recommended (see section Interactions with other medicinal products and other forms of interactions).

CADUET should not be administered simultaneously with fusidic acid in systemic form, and for up to 7 days after stopping treatment with fusidic acid. In patients where the use of systemic fusidic acid is considered essential, statin therapy should be discontinued for the duration of fusidic acid therapy. Cases of rhabdomyolysis (some fatal) have been reported in patients receiving fusidic acid and a statin in combination (see section Interactions with other medicinal products and other forms of interactions). Patients should be informed of the need to seek immediate medical attention if they experience symptoms of muscle weakness, pain, or muscle tenderness.

Statin therapy can be restarted seven days after the last dose of fusidic acid.

In exceptional circumstances, when prolonged treatment with systemic fusidic acid is required, e.g. for the treatment of severe infections, the need for co-administration of CADUET and fusidic acid should only be considered in cases of per case and under close medical supervision.

Prevention of stroke by aggressively lowering cholesterol levels (SPARCL study)

In a posteriori analysis performed in subgroups of patients with recent stroke or transient ischemic attack (TIA) but without coronary artery disease, a higher frequency of hemorrhagic stroke was observed in treated patients. per 80 mg atorvastatin compared to patients on placebo.

This high risk is particularly observed in patients who have already had a hemorrhagic stroke or a lacunar infarction at the inclusion of the study.

In patients with a history of hemorrhagic stroke or lacunar infarction, the benefit / risk balance of atorvastatin 80 mg is uncertain. Therefore, the potential risk of occurrence of haemorrhagic stroke should be carefully assessed before any initiation of treatment (see section Pharmacodynamic properties).

Interstitial lung disease

Cases of interstitial lung disease have exceptionally been reported with certain statins, particularly during long-term therapy .

Symptoms may include dyspnea, a non-productive cough, and altered general condition (fatigue, weight loss, and fever). If interstitial lung disease is suspected in a patient, statin therapy should be discontinued.

Diabetes

There is some evidence that statins, as a pharmacological class, increase blood sugar. In some patients at high risk of developing diabetes, statins may cause hyperglycaemia requiring the initiation of diabetes treatment. This risk is nevertheless compensated by the reduction in the vascular risk under statins and therefore it should not be a reason for stopping statins. Patients at risk (fasting blood glucose between 5.6 and 6.9 mmol / l, BMI> 30 kg / m², increased triglyceride levels, arterial hypertension) should be monitored clinically and biologically in accordance with national recommendations.

PREGNANCY & BREAST-FEEDING & FERTILITY

Caduet is contraindicated during pregnancy and lactation.

Women of childbearing age

Women of childbearing potential should use reliable contraceptive measures during treatment ( see Contraindications ).

Pregnancy

The safety of atorvastatin has not been established in pregnant women. No controlled clinical trials have been performed in pregnant women treated with atorvastatin. Following intrauterine exposure to HMG-CoA reductase inhibitors, birth defects have rarely been reported. Studies in animals have shown reproductive toxicity ( see Preclinical safety ).

Treatment of the mother with atorvastatin may reduce the fetal level of mevalonate, which is a precursor of cholesterol biosynthesis. Atherosclerosis is a chronic process, and stopping a lipid-lowering drug during pregnancy should generally have little effect on the long-term risk associated with primary hypercholesterolemia.

For these reasons, Caduet should not be used during pregnancy, or in a woman planning to become pregnant or in whom pregnancy is suspected. Caduet treatment should be withheld during pregnancy or until it has been determined that the woman is not pregnant ( see Contraindications ).

If pregnancy is discovered during treatment, it should be stopped immediately.

Feeding with milk

Amlodipine is excreted in breast milk. The proportion of maternal dose received by the infant has been estimated at an interquartile range of 3-7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. The excretion of atorvastatin or its metabolites in human milk is not known. In rats, the plasma concentrations of atorvastatin and its metabolites are similar to those found in milk ( see Preclinical safety ). Due to the possibility of serious side effects, women treated with Caduet should not breast-feed their infants ( see Contraindications ). Atorvastatin is contraindicated during breastfeeding ( see Contraindications ).

Fertility

No effect of atorvastatin on fertility has been demonstrated in studies conducted in male or female animals ( see Preclinical Safety ).

Reversible biochemical changes in the sperm head have been reported in some patients treated with calcium channel blockers. There is insufficient clinical data regarding the potential effect of amlodipine on fertility. In a study carried out in rats, adverse effects were detected on male fertility ( see Preclinical safety ).

What happens if I overdose from Caduet?

No information is available regarding overdose of Caduet in humans.

Amlodipine:

For amlodipine, experience with intentional overdose in humans is limited. Massive overdose could cause extensive peripheral vasodilation and possibly reflex tachycardia. Marked and possibly prolonged systemic hypotension up to and including shock with fatal outcome has been reported. Any hypotension resulting from acute intoxication requires monitoring in an intensive cardiological care unit. A vasoconstrictor can be used to restore vascular tone and blood pressure. Since amlodipine is highly protein bound, dialysis is unlikely to provide any benefit.

Atorvastatin:

There is no specific treatment for atorvastatin overdose. In the event of overdose, the patient should receive symptomatic treatment and supportive measures should be implemented as needed. Liver function and serum CK concentrations should be monitored. Due to the strong binding of the drug to plasma proteins, hemodialysis is not expected to significantly increase the clearance of atorvastatin.

What should I do if I miss a dose?

If you forget to take CADUET 5/ 10 mg -5/ 10 mg film-coated tablets:

If you forget to take your dose of CADUET, take your next dose at the normal time.

Do not take a double dose to make up for the dose you forgot to take.

What is Forms and Composition ?

SHAPES and PRESENTATIONS

5 mg / 10 mg film-coated tablet (oval, debossed with “Pfizer” on one side and “CDT 051” on the other side; white) and 10 mg / 10 mg (oval, debossed with “Pfizer “On one side and” CDT 101 “on the other side; blue): Boxes of 30 and 90, in blisters.

COMPOSITION

p cp Amlodipine (INN) as amlodipine besilate 5 mg or 10 mg Atorvastatin (INN) as atorvastatin calcium trihydrate 10 mg

Excipients (common): Core: calcium carbonate, croscarmellose sodium, microcrystalline cellulose, pregelatinized corn starch, polysorbate 80, hydroxypropylcellulose, colloidal anhydrous silica, magnesium stearate. Film- coating : 5 mg / 10 mg tablet: Opadry II white 85F28751 (polyvinyl alcohol, titanium dioxide E171, macrogol 3000, talc). 10 mg / 10 mg tablet: Opadry II blue 85F10919 (polyvinyl alcohol, titanium dioxide E171, macrogol 3000, talc, indigo carmine aluminum lake E132).

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post caduet tablets Uses, Dosage, Side Effects, Precautions & Warnings appeared first on Drug Online.

from Drug Online https://bit.ly/3lxi9nO via Edrug Online from faculty of medicine https://bit.ly/3gLbi6L via Faculty of Medicine

#medicines #including Allergy Medicines #Anemia #Antibiotic Medicines #Colds & Flu Medicines #Cough Me

0 notes

colinfitzpatrick · 4 years ago